Literature DB >> 3723994

[Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

H Rückle, G Ehninger, F Jakob, K Wilms.   

Abstract

Thirteen patients with cytologically or histologically confirmed ascites from various malignancies have received 37 courses of intraperitoneal cis-platinum (cDDP). The tumor had to be confined to the peritoneal cavity or cause major symptoms by peritoneal carcinosis. cDDP (90-150 mg/m2 in 21 saline) was administered intraperitoneally with concurrent i.v. infusion of sodium thiosulfate. Courses were repeated in 4-week intervals. Total platinum was assayed by flameless atomic absorption spectrophotometry. With a dwell of 4 h 31.5 +/- 17.2% of platinum was recovered. Mean peak platinum concentration in the peritoneal cavity was 54.6 +/- 21 micrograms/ml and that in serum was 2.6 +/- 1.1 micrograms/ml. The ratio of peritoneal to serum platinum concentration dropped from 41 +/- 18.2 after 1 h to 6.9 +/- 4.7 after 5 h. The area under the curve for the peritoneum was approximately 11-fold greater than the area under the curve for serum. Within 12 h 31.7 +/- 10.7% of the administered dose was excreted in urine. Ten patients had disappearance of ascites lasting 6-135 + weeks. The treatment was generally well tolerated, no serious side effects were observed. This study demonstrates a pharmacokinetic advantage of intraperitoneal chemotherapy with cDDP and an effectiveness against peritoneal carcinosis from various malignancies with minimal systemic toxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3723994     DOI: 10.1007/bf01713172

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  33 in total

1.  Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.

Authors:  R F Ozols; R C Young; J L Speyer; P H Sugarbaker; R Greene; J Jenkins; C E Myers
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

2.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

3.  Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.

Authors:  M Markman; S Cleary; W E Lucas; S B Howell
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

4.  [Intraperitoneal cisplatin in peritoneal carcinomatosis patients].

Authors:  M Toi; T Shiramizu; T Yonemura; T Ezaki; N Oka; T Yoshida; H Tsurumaru
Journal:  Gan No Rinsho       Date:  1985-05

5.  High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.

Authors:  R B Jones; J M Collins; C E Myers; A E Brooks; S M Hubbard; J E Balow; M F Brennan; R L Dedrick; V T DeVita
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

6.  The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.

Authors:  J L Speyer; C E Myers
Journal:  Recent Results Cancer Res       Date:  1980

7.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

Authors:  S B Howell; R Taetle
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

8.  Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system.

Authors:  J W Gyves; W D Ensminger; P Stetson; J E Niederhuber; M Meyer; S Walker; M A Janis; S Gilbertson
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

9.  Intracavitary bleomycin in the management of malignant effusions: a multicenter study.

Authors:  M J Ostrowski; G M Halsall
Journal:  Cancer Treat Rep       Date:  1982-11

10.  Clinical pharmacology of intraperitoneal cisplatin.

Authors:  J A Lopez; J G Krikorian; S D Reich; R D Smyth; F H Lee; B F Issell
Journal:  Gynecol Oncol       Date:  1985-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.